China Resources Pharmaceutical (03320.HK) -0.110 (-1.792%) Short selling $65.09M; Ratio 42.540% announced that Shenzhou Bio, a business unit under China Resources Double-Crane, achieved a significant breakthrough in the industrial application of synthetic biology. Its core bio-based product, 1,4-butanediamine, has been successfully incorporated into the newly launched Wouper PA46 bio-based high-performance polyamide material system of downstream partner Wote Co., Ltd., marking the Group's official entry into the terminal application field of high-performance materials.The Wouper PA46 launched by Wote Co., Ltd. is positioned as a benchmark bio-based high-performance polyamide product. The material integrates the green attributes of bio-based raw materials with the stringent operating requirements of high-performance engineering plastics. It features multiple outstanding properties, including high strength, low creep, fatigue resistance, wide-temperature wear resistance, self-lubrication, high fluidity, weld resistance, oil resistance and hydrolysis resistance. It can be widely applied in high-end manufacturing sectors such as automotive transmission systems, precision electronics and the electrical industry, demonstrating strong downstream application potential. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-22 16:25.)
AASTOCKS Financial News